UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers.
Data-focused CRO Quanticate (Hitchin, UK) will partner with cancer research organisation Cancer Research UK to support the launch of their DETERMINE study, testing a range of therapies targeting key genetic mutations in cancer cells, a first of its kind in the UK.
The DETERMINE study will focus on patients with rare cancers in order to investigate the utilisation of existing licensed drugs for the treatment of particular rare cancers. Individuals with an identifiable genetic alteration in their cancer will form cohorts to be targeted by treatments already approved for other cancer types. As a data-focused CRO with a primary focus on data capture, statistical analysis, and clinical trial report, Quanticate will work with Cancer Research UK’s Centre for Drug Development to ensure the optimisation of the study’s statistical design.
Commenting on Quanticate’s role in the DETERMINE study, CEO David Underwood stated: “The study will strive to improve the outcome for patients who may have run out of options during their cancer journey... Cancer Research UK has asked adults, young people, and children who are suffering with a rare type of cancer to come forward with the possibility that there may be an existing approved drug that could benefit them. Furthermore, analyss from this study could also open up successful treatment options for other patients with similar cancer types who are not enrolled on the trial.” The study is slated to commence across the UK from September 2022, with approximately 15–20 treatment branches each with initial trial cohorts of 30 evaluable patients.
Underwood further commented: “Quanticate is delighted to partner with Cancer Research UK for a program so close to home for many people and we are hopeful that the study will be successful in finding results that will improve the quality of life for many patients.”
Nigel Blackburn, Director of Cancer Research UK’s Centre for Drug Development, added, “We’re delighted to partner with Quanticate and welcome the valuable expertise they bring to this incredibly important trial which will allow potentially life-saving treatments to be opened up to people with rare cancers.”
Related News
-
News MedPharm and Mosanna collaboration to develop novel Metabolic Obstructive Sleep Apnea treatment
A collaboration between development and manufacturing services company MedPharm and biotech company Mosanna aims to develop and deliver a nasal spray treatment for a form of sleep apnea. -
News Partnership between Bora Pharmaceuticals and TaiRx, Inc. for anticancer drug manufacturing
A partnership between Bora Pharmaceuticals and TaiRx, Inc. is expected to support the manufacturing of breakthrough anticancer drug CVM-1118, with two phase II clinical trials to commence. -
News Expansion of Quotient Sciences' UK drug development and manufacturing facilities
Quotient Sciences’ Nottingham and Reading facilities have announced the completion of their facility expansions, providing further capabilities to support their flagship program Translational Pharmaceutics®. -
News The Korean biopharma market: Incentivizing innovation
With new drug approvals hitting a record high in 2021 and unprecedented number of out-licensing deals closed in 2020, Korean pharmaceutical companies and CDMO’s are poised for significant market growth [i]. -
News Biden's $2 billion Biotech Boost
President Biden issues executive order to bolster U.S. biomanufacturing sector. -
News Phase III trials of Pfizer’s mRNA-based influenza vaccine begin
Leveraging their current mRNA vaccine technology developed during the COVID-19 pandemic, Pfizer have announced the start of phase III trials for a potential mRNA-based influenza vaccine. -
News mRNA therapy for ovarian cancer and muscle wasting
Researchers demonstrate results of a promising mRNA therapy for ovarian cancer and muscle wasting caused by cachexia, a condition associated with various types of cancers and chronic diseases. -
News Pfizer CentreOne Content Refinement Q3 media buy
For 40 years Pfizer CentreOne has been guiding drug projects to success. Here’s how our services make us an altogether different kind of CDMO:
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance